Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Schenone

Showing results (1-10 of 173) with videos related to

Pageof 18
Sort By:
Pharmaceutics|May 25, 2024
Unlocking Potential and Limits of Kinase Inhibitors: The Highway to Enhanced Cancer Targeted TherapyFrancesca Musumeci, Silvia Schenone
Organic & Biomolecular Chemistry|July 8, 2009
Recent highlights in the synthesis of highly functionalized pyrimidinesMarco Radi, Silvia Schenone, Maurizio Botta
Current Pharmaceutical Biotechnology|March 21, 2012
Allosteric inhibitors of Bcr-Abl: towards novel myristate-pocket bindersMarco Radi, Silvia Schenone, Maurizio Botta
Current Pharmaceutical Design|December 17, 2010
Using insights into Pim1 structure to design new anticancer drugsSilvia Schenone, Cristina Tintori, Maurizio Botta
Anti-Cancer Agents in Medicinal Chemistry|November 30, 2007
Synthetic SRC-kinase domain inhibitors and their structural requirementsSilvia Schenone, Fabrizio Manetti, Maurizio Botta
Future Medicinal Chemistry|April 26, 2012
An update on dual Src/Abl inhibitorsFrancesca Musumeci, Silvia Schenone, Chiara Brullo, et al.
Expert Opinion on Investigational Drugs|June 19, 2010
Novel dual Src/Abl inhibitors for hematologic and solid malignanciesSilvia Schenone, Chiara Brullo, Francesca Musumeci, et al.
European Journal of Medicinal Chemistry|August 30, 2008
Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitorsCristina Tintori, Matteo Magnani, Silvia Schenone, et al.
Archiv Der Pharmazie|June 12, 2009
Parallel synthesis of O-phenoxyethyl and O-adamantyl N-acyl thiocarbamates endowed with antiproliferative activityAndrea Spallarossa, Sara Cesarini, Silvia Schenone, et al.
Journal of Medicinal Chemistry|October 27, 2012
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitorsFrancesca Musumeci, Marco Radi, Chiara Brullo, et al.
Pageof 18

Showing results (1-10 of 173) with videos related to

Sort By:
Pageof 18
Pharmaceutics|May 25, 2024
Unlocking Potential and Limits of Kinase Inhibitors: The Highway to Enhanced Cancer Targeted TherapyFrancesca Musumeci, Silvia Schenone
Organic & Biomolecular Chemistry|July 8, 2009
Recent highlights in the synthesis of highly functionalized pyrimidinesMarco Radi, Silvia Schenone, Maurizio Botta
Current Pharmaceutical Biotechnology|March 21, 2012
Allosteric inhibitors of Bcr-Abl: towards novel myristate-pocket bindersMarco Radi, Silvia Schenone, Maurizio Botta
Current Pharmaceutical Design|December 17, 2010
Using insights into Pim1 structure to design new anticancer drugsSilvia Schenone, Cristina Tintori, Maurizio Botta
Anti-Cancer Agents in Medicinal Chemistry|November 30, 2007
Synthetic SRC-kinase domain inhibitors and their structural requirementsSilvia Schenone, Fabrizio Manetti, Maurizio Botta
Future Medicinal Chemistry|April 26, 2012
An update on dual Src/Abl inhibitorsFrancesca Musumeci, Silvia Schenone, Chiara Brullo, et al.
Expert Opinion on Investigational Drugs|June 19, 2010
Novel dual Src/Abl inhibitors for hematologic and solid malignanciesSilvia Schenone, Chiara Brullo, Francesca Musumeci, et al.
European Journal of Medicinal Chemistry|August 30, 2008
Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitorsCristina Tintori, Matteo Magnani, Silvia Schenone, et al.
Archiv Der Pharmazie|June 12, 2009
Parallel synthesis of O-phenoxyethyl and O-adamantyl N-acyl thiocarbamates endowed with antiproliferative activityAndrea Spallarossa, Sara Cesarini, Silvia Schenone, et al.
Journal of Medicinal Chemistry|October 27, 2012
Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitorsFrancesca Musumeci, Marco Radi, Chiara Brullo, et al.
Pageof 18